Mark R. Forwood
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mark R. Forwood has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Blessing Crimeen-Irwin
St. Vincent's Institute of Medical Research Fitzroy Victoria Australia
3 shared publications- Natalie A. Sims
St. Vincent’s Institute of Medical Research
3 shared publications - Niloufar Ansari
Bone Biology and Disease Unit, St. Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, Melbourne, VIC, 3065, Australia
3 shared publications - Thomas John Martin
Bone Biology and Disease Unit, St. Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, Melbourne, VIC, 3065, Australia
3 shared publications - Christina Vrahnas
Bone Biology and Disease Unit, St. Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, Melbourne, VIC, 3065, Australia
2 shared publications - Cyril Petibois
University of Bordeaux, Inserm U1029 LAMC, Allée Geoffroy Saint-Hilaire Bat. B2, 33600, Pessac, France
2 shared publications
Latest Publications
- Open Access
- 21 June 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (15) , 16221-16230
MCP‐1 expression in breast cancer and its association with distant relapse
Background: Distant relapse of breast cancer complicates management of the disease and accounts for 90% of breast cancer‐related deaths. Monocyte chemoattractant protein‐1 (MCP‐1) has critical roles in breast cancer progression and is widely accepted as a pro‐metastatic chemokine.Methods: This study explored MCP‐1 expression in the primary tumour of 251 breast cancer patients. A simplified ‘histoscore’ was used to determine if each tumour had high or low expression of MCP‐1. Patient breast cancers were retrospectively staged based on available patient data. p < 0.05 was used to determine significance and changes in hazard ratios between models were considered.Results: Low MCP‐1 expression in the primary tumour was associated with breast cancer‐related death with distant relapse in ER− breast cancers (p < 0.01); however, this was likely a result of most low MCP‐1‐expressing ER− breast cancers being Stage III or Stage IV, with high MCP‐1 expression in the primary tumour significantly correlated with Stage I breast cancers (p < 0.05). Expression of MCP‐1 in the primary ER− tumours varied across Stage I, II, III and IV and we highlighted a switch in MCP‐1 expression from high in Stage I ER− cancers to low in Stage IV ER− cancers.Conclusion: This study has emphasised a critical need for further investigation into MCP‐1's role in breast cancer progression and improved characterisation of MCP‐1 in breast cancers, particularly in light of the development of anti‐MCP‐1, anti‐metastatic therapies.
- 21 June 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (15) , 16221-16230
Open AccessMCP‐1 expression in breast cancer and its association with distant relapse
Background: Distant relapse of breast cancer complicates management of the disease and accounts for 90% of breast cancer‐related deaths. Monocyte chemoattractant protein‐1 (MCP‐1) has critical roles in breast cancer progression and is widely accepted as a pro‐metastatic chemokine.Methods: This study explored MCP‐1 expression in the primary tumour of 251 breast cancer patients. A simplified ‘histoscore’ was used to determine if each tumour had high or low expression of MCP‐1. Patient breast cancers were retrospectively staged based on available patient data. p < 0.05 was used to determine significance and changes in hazard ratios between models were considered.Results: Low MCP‐1 expression in the primary tumour was associated with breast cancer‐related death with distant relapse in ER− breast cancers (p < 0.01); however, this was likely a result of most low MCP‐1‐expressing ER− breast cancers being Stage III or Stage IV, with high MCP‐1 expression in the primary tumour significantly correlated with Stage I breast cancers (p < 0.05). Expression of MCP‐1 in the primary ER− tumours varied across Stage I, II, III and IV and we highlighted a switch in MCP‐1 expression from high in Stage I ER− cancers to low in Stage IV ER− cancers.Conclusion: This study has emphasised a critical need for further investigation into MCP‐1's role in breast cancer progression and improved characterisation of MCP‐1 in breast cancers, particularly in light of the development of anti‐MCP‐1, anti‐metastatic therapies.
- Open Access
- 1 December 2020
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 36 (10) , 1999-2016
Dmp1Cre-directed knockdown of parathyroid hormone–related protein (PTHrP) in murine decidua is associated with a life-long increase in bone mass, width, and strength in male progeny
Parathyroid hormone–related protein (PTHrP, gene name Pthlh) is a pleiotropic regulator of tissue homeostasis. In bone, Dmp1Cre-targeted PTHrP deletion in osteocytes causes osteopenia and impaired cortical strength. We report here that this outcome depends on parental genotype. In contrast to our previous report using mice bred from heterozygous (flox/wild type) Dmp1Cre.Pthlhf/w parents, adult (16-week-old and 26-week-old) flox/flox (f/f) Dmp1Cre.Pthlhf/f mice from homozygous parents (Dmp1Cre.Pthlhf/f(hom)) have stronger bones, with 40% more trabecular bone mass and 30% greater femoral width than controls. This greater bone size was observed in Dmp1Cre.Pthlhf/f(hom) mice as early as 12 days of age, when greater bone width was also found in male and female Dmp1Cre.Pthlhf/f(hom) mice compared to controls, but not in gene-matched mice from heterozygous parents. This suggested a maternal influence on skeletal size prior to weaning. Although Dmp1Cre has previously been reported to cause gene recombination in mammary gland, milk PTHrP protein levels were normal. The wide-bone phenotype was also noted in utero: Dmp1Cre.Pthlhf/f(hom) embryonic femurs were more mineralized and wider than controls. Closer examination revealed that Dmp1Cre caused PTHrP recombination in placenta, and in the maternal-derived decidual layer that resides between the placenta and the uterus. Decidua from mothers of Dmp1Cre.Pthlhf/f(hom) mice also exhibited lower PTHrP levels by immunohistochemistry and were smaller than controls. We conclude that Dmp1Cre leads to gene recombination in decidua, and that decidual PTHrP might, through an influence on decidual cells, limit embryonic bone radial growth. This suggests a maternal-derived developmental origin of adult bone strength. © 2021 American Society for Bone and Mineral Research (ASBMR).
- 1 December 2020
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 36 (10) , 1999-2016
Open AccessDmp1Cre-directed knockdown of parathyroid hormone–related protein (PTHrP) in murine decidua is associated with a life-long increase in bone mass, width, and strength in male progeny
Parathyroid hormone–related protein (PTHrP, gene name Pthlh) is a pleiotropic regulator of tissue homeostasis. In bone, Dmp1Cre-targeted PTHrP deletion in osteocytes causes osteopenia and impaired cortical strength. We report here that this outcome depends on parental genotype. In contrast to our previous report using mice bred from heterozygous (flox/wild type) Dmp1Cre.Pthlhf/w parents, adult (16-week-old and 26-week-old) flox/flox (f/f) Dmp1Cre.Pthlhf/f mice from homozygous parents (Dmp1Cre.Pthlhf/f(hom)) have stronger bones, with 40% more trabecular bone mass and 30% greater femoral width than controls. This greater bone size was observed in Dmp1Cre.Pthlhf/f(hom) mice as early as 12 days of age, when greater bone width was also found in male and female Dmp1Cre.Pthlhf/f(hom) mice compared to controls, but not in gene-matched mice from heterozygous parents. This suggested a maternal influence on skeletal size prior to weaning. Although Dmp1Cre has previously been reported to cause gene recombination in mammary gland, milk PTHrP protein levels were normal. The wide-bone phenotype was also noted in utero: Dmp1Cre.Pthlhf/f(hom) embryonic femurs were more mineralized and wider than controls. Closer examination revealed that Dmp1Cre caused PTHrP recombination in placenta, and in the maternal-derived decidual layer that resides between the placenta and the uterus. Decidua from mothers of Dmp1Cre.Pthlhf/f(hom) mice also exhibited lower PTHrP levels by immunohistochemistry and were smaller than controls. We conclude that Dmp1Cre leads to gene recombination in decidua, and that decidual PTHrP might, through an influence on decidual cells, limit embryonic bone radial growth. This suggests a maternal-derived developmental origin of adult bone strength. © 2021 American Society for Bone and Mineral Research (ASBMR).
- Open Access
- 4 November 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 5073
Author Correction: Increased autophagy in EphrinB2-deficient osteocytes is associated with elevated secondary mineralization and brittle bone
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- 4 November 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 5073
Open AccessAuthor Correction: Increased autophagy in EphrinB2-deficient osteocytes is associated with elevated secondary mineralization and brittle bone
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- Open Access
- 31 July 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-16
Increased autophagy in EphrinB2-deficient osteocytes is associated with elevated secondary mineralization and brittle bone
Mineralized bone forms when collagen-containing osteoid accrues mineral crystals. This is initiated rapidly (primary mineralization), and continues slowly (secondary mineralization) until bone is remodeled. The interconnected osteocyte network within the bone matrix differentiates from bone-forming osteoblasts; although osteoblast differentiation requires EphrinB2, osteocytes retain its expression. Here we report brittle bones in mice with osteocyte-targeted EphrinB2 deletion. This is not caused by low bone mass, but by defective bone material. While osteoid mineralization is initiated at normal rate, mineral accrual is accelerated, indicating that EphrinB2 in osteocytes limits mineral accumulation. No known regulators of mineralization are modified in the brittle cortical bone but a cluster of autophagy-associated genes are dysregulated. EphrinB2-deficient osteocytes displayed more autophagosomes in vivo and in vitro, and EphrinB2-Fc treatment suppresses autophagy in a RhoA-ROCK dependent manner. We conclude that secondary mineralization involves EphrinB2-RhoA-limited autophagy in osteocytes, and disruption leads to a bone fragility independent of bone mass.
- 31 July 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-16
Open AccessIncreased autophagy in EphrinB2-deficient osteocytes is associated with elevated secondary mineralization and brittle bone
Mineralized bone forms when collagen-containing osteoid accrues mineral crystals. This is initiated rapidly (primary mineralization), and continues slowly (secondary mineralization) until bone is remodeled. The interconnected osteocyte network within the bone matrix differentiates from bone-forming osteoblasts; although osteoblast differentiation requires EphrinB2, osteocytes retain its expression. Here we report brittle bones in mice with osteocyte-targeted EphrinB2 deletion. This is not caused by low bone mass, but by defective bone material. While osteoid mineralization is initiated at normal rate, mineral accrual is accelerated, indicating that EphrinB2 in osteocytes limits mineral accumulation. No known regulators of mineralization are modified in the brittle cortical bone but a cluster of autophagy-associated genes are dysregulated. EphrinB2-deficient osteocytes displayed more autophagosomes in vivo and in vitro, and EphrinB2-Fc treatment suppresses autophagy in a RhoA-ROCK dependent manner. We conclude that secondary mineralization involves EphrinB2-RhoA-limited autophagy in osteocytes, and disruption leads to a bone fragility independent of bone mass.
- 1 May 2013
- Published by Bioscientifica in Bone Abstracts
Vitamin D levels of > 85 nmol/l in the presence of adequate dietary Ca minimise bone turnover and improve bone strength
We have reported femoral osteopenia in short term-vitamin D restricted rats without deterioration in tibial cortical bone volume (CBV), geometry or strength1. This study aimed to establish the effect of extended vitamin D deficiency in aged rat tibial volume and strength. Female Sprague-Dawley rats (9 m, n=6/group) were fed a diet containing varying vitamin D3 (D) levels (0, 2, 12, and 20 IU/day) with either low (0.1%, LCa) or high (1%, HCa) dietary calcium for 6 m. At 15 m blood was taken for 25 hydroxyvitamin D (25D) 1.25 dihydroxyvitamin D (1.25D), PTH and Ca analyses and tibiae and femora retrieved for bone analyses. 3D micro-CT scans (Skyscan 1174) were used to determine CBV, mid-shaft sagittal cortical thickness (Cth.sag) and metaphyseal BV/TV. Tibial peak load was determined by three-point bending (Test Resources 800LE4). 25D and 1.25D were determined by RIA (IDS) and PTH by IRMA (Immutopics). Group serum 25D levels ranged from 22 (±2.9) to 161 (±38.8) nmol/l and serum calcium levels from 2.5 (±0.05) to 3.2 (±0.2) mmol/l. Circulating 25D was a determinant of BV/TV (r2=0.23, Pr2=0.22, P3/μm2 per day): LCa20D 33.9 (3.4) vs HCa20D 21.8 (2.3), Pn×10−3/mm): LCa20D 2.0 (0.2) vs HCa20D 1.1 (0.1), Pr2=0.39, P2,3 in combination with the present findings suggest that the mechanism for vitamin D-optimisation of bone is not mediated via a calcaemic effect. 1. Lee AMC et al. JSBMB 121 284–287, 2010. 2. Anderson PH et al. JBMR 23 1789–97, 2008. 3. Anderson PH et al. JSBMB 121 288–921, 2010.
- 1 May 2013
- Published by Bioscientifica in Bone Abstracts
Vitamin D levels of > 85 nmol/l in the presence of adequate dietary Ca minimise bone turnover and improve bone strength
We have reported femoral osteopenia in short term-vitamin D restricted rats without deterioration in tibial cortical bone volume (CBV), geometry or strength1. This study aimed to establish the effect of extended vitamin D deficiency in aged rat tibial volume and strength. Female Sprague-Dawley rats (9 m, n=6/group) were fed a diet containing varying vitamin D3 (D) levels (0, 2, 12, and 20 IU/day) with either low (0.1%, LCa) or high (1%, HCa) dietary calcium for 6 m. At 15 m blood was taken for 25 hydroxyvitamin D (25D) 1.25 dihydroxyvitamin D (1.25D), PTH and Ca analyses and tibiae and femora retrieved for bone analyses. 3D micro-CT scans (Skyscan 1174) were used to determine CBV, mid-shaft sagittal cortical thickness (Cth.sag) and metaphyseal BV/TV. Tibial peak load was determined by three-point bending (Test Resources 800LE4). 25D and 1.25D were determined by RIA (IDS) and PTH by IRMA (Immutopics). Group serum 25D levels ranged from 22 (±2.9) to 161 (±38.8) nmol/l and serum calcium levels from 2.5 (±0.05) to 3.2 (±0.2) mmol/l. Circulating 25D was a determinant of BV/TV (r2=0.23, Pr2=0.22, P3/μm2 per day): LCa20D 33.9 (3.4) vs HCa20D 21.8 (2.3), Pn×10−3/mm): LCa20D 2.0 (0.2) vs HCa20D 1.1 (0.1), Pr2=0.39, P2,3 in combination with the present findings suggest that the mechanism for vitamin D-optimisation of bone is not mediated via a calcaemic effect. 1. Lee AMC et al. JSBMB 121 284–287, 2010. 2. Anderson PH et al. JBMR 23 1789–97, 2008. 3. Anderson PH et al. JSBMB 121 288–921, 2010.